SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059114
Filing Date
2024-05-14
Accepted
2024-05-14 08:24:14
Documents
67
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acor-20240331.htm   iXBRL 10-Q 1162230
2 EX-31.1 acor-ex31_1.htm EX-31.1 11345
3 EX-31.2 acor-ex31_2.htm EX-31.2 10682
4 EX-32.1 acor-ex32_1.htm EX-32.1 6731
5 EX-32.2 acor-ex32_2.htm EX-32.2 6831
  Complete submission text file 0000950170-24-059114.txt   6600591

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acor-20240331.xsd EX-101.SCH 1260854
71 EXTRACTED XBRL INSTANCE DOCUMENT acor-20240331_htm.xml XML 961102
Mailing Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965
Business Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965 914-347-4300
Acorda Therapeutics, Inc. (Filer) CIK: 0001008848 (see all company filings)

IRS No.: 133831168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-31938 | Film No.: 24941552
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)